JP2025501746A - ウイルス感染症の治療における使用のための酵母から産生されたアルファ－１アンチトリプシン - Google Patents
ウイルス感染症の治療における使用のための酵母から産生されたアルファ－１アンチトリプシン Download PDFInfo
- Publication number
- JP2025501746A JP2025501746A JP2024537865A JP2024537865A JP2025501746A JP 2025501746 A JP2025501746 A JP 2025501746A JP 2024537865 A JP2024537865 A JP 2024537865A JP 2024537865 A JP2024537865 A JP 2024537865A JP 2025501746 A JP2025501746 A JP 2025501746A
- Authority
- JP
- Japan
- Prior art keywords
- aat
- fragment
- recombinant
- protein
- yeast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/84—Pichia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216836 | 2021-12-22 | ||
| EP21216836.3 | 2021-12-22 | ||
| EP22166483.2 | 2022-04-04 | ||
| EP22166483 | 2022-04-04 | ||
| PCT/EP2022/087461 WO2023118424A1 (en) | 2021-12-22 | 2022-12-22 | Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025501746A true JP2025501746A (ja) | 2025-01-23 |
| JP2025501746A5 JP2025501746A5 (https=) | 2025-12-08 |
Family
ID=84980906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537865A Pending JP2025501746A (ja) | 2021-12-22 | 2022-12-22 | ウイルス感染症の治療における使用のための酵母から産生されたアルファ－１アンチトリプシン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250057927A1 (https=) |
| EP (1) | EP4453233A1 (https=) |
| JP (1) | JP2025501746A (https=) |
| AU (1) | AU2022422304A1 (https=) |
| CA (1) | CA3241852A1 (https=) |
| IL (1) | IL313247A (https=) |
| TW (1) | TW202334430A (https=) |
| WO (1) | WO2023118424A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4480960A1 (en) * | 2023-06-22 | 2024-12-25 | AATEC Medical GmbH | A recombinant human alpha-1 antitrypsin glycoprotein |
| EP4730999A1 (en) * | 2023-06-22 | 2026-04-29 | AATEC Medical GmbH | Recombinant aat from yeast to treat transplants |
| CN121752288A (zh) * | 2023-06-22 | 2026-03-27 | 阿泰克医疗有限公司 | 重组人α-1抗胰蛋白酶糖蛋白 |
| WO2024261179A1 (en) * | 2023-06-22 | 2024-12-26 | Aatec Medical Gmbh | Recombinant aat from yeast to treat bacterial respiratory infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713249A (en) | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
| US5266333A (en) | 1985-03-06 | 1993-11-30 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone |
| US5417982A (en) | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| WO2021191900A1 (en) | 2020-03-26 | 2021-09-30 | Kamada Ltd. | Methods for treating infectious diseases caused by coronavirus |
-
2022
- 2022-12-22 TW TW111149485A patent/TW202334430A/zh unknown
- 2022-12-22 EP EP22843749.7A patent/EP4453233A1/en active Pending
- 2022-12-22 AU AU2022422304A patent/AU2022422304A1/en active Pending
- 2022-12-22 US US18/723,224 patent/US20250057927A1/en active Pending
- 2022-12-22 JP JP2024537865A patent/JP2025501746A/ja active Pending
- 2022-12-22 IL IL313247A patent/IL313247A/en unknown
- 2022-12-22 CA CA3241852A patent/CA3241852A1/en active Pending
- 2022-12-22 WO PCT/EP2022/087461 patent/WO2023118424A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3241852A1 (en) | 2023-06-29 |
| US20250057927A1 (en) | 2025-02-20 |
| TW202334430A (zh) | 2023-09-01 |
| EP4453233A1 (en) | 2024-10-30 |
| IL313247A (en) | 2024-08-01 |
| WO2023118424A1 (en) | 2023-06-29 |
| AU2022422304A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250057927A1 (en) | Alpha-1 antitrypsin produced from yeast for use in the treatment of viral infections | |
| US20230414730A1 (en) | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections | |
| US9421243B2 (en) | Therapy for influenza like illness | |
| CN118434880A (zh) | 由酵母生产的α-1抗胰蛋白酶用于治疗病毒感染的用途 | |
| EP3995130A1 (en) | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections | |
| WO2021164576A1 (zh) | 用于抗冠状病毒感染的药物及其应用 | |
| JP2022527082A (ja) | コラーゲン７組成物を産生するための系および方法 | |
| KR20260030111A (ko) | 재조합 인간 알파-1 항트립신 당단백질 | |
| EP4480960A1 (en) | A recombinant human alpha-1 antitrypsin glycoprotein | |
| KR20080071116A (ko) | 기도에 영향을 미치는 염증 질환에 있어서 활성화 단백질ｃ의 기도 투여법 | |
| EP4731251A1 (en) | Recombinant aat from yeast to treat bacterial respiratory infections | |
| IL325205A (en) | Recombinant human alpha-1 antitrypsin glycoprotein for use in the treatment of inflammatory lung diseases | |
| EP4426335A1 (en) | Das181 variant compositions | |
| CN121653105A (zh) | 中性粒细胞弹性蛋白酶的融合蛋白及其制备方法与应用 | |
| WO2022207918A1 (en) | COVID-19 Therapy | |
| HK40090471A (zh) | Ace2-fc融合蛋白及其用途 | |
| KIDO et al. | Influenza Virus, Sendai Virus, and HIV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251127 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251127 |